CRISPR Gene Editing Market by Offering (Reagents & Consumables, Services, Software & Systems), Technology (Anti-CRISPR Proteins, CRISPR/Cas13, CRISPR/Cas9), Application, End-use - Global Forecast 2024-2030

CRISPR Gene Editing Market by Offering (Reagents & Consumables, Services, Software & Systems), Technology (Anti-CRISPR Proteins, CRISPR/Cas13, CRISPR/Cas9), Application, End-use - Global Forecast 2024-2030

The CRISPR Gene Editing Market size was estimated at USD 3.25 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 16.81% to reach USD 9.66 billion by 2030.

CRISPR gene editing, referred to as CRISPR-Cas9, is a revolutionary biochemical technology that enables geneticists and medical researchers to edit and modify parts of the genome by adding, removing, and altering parts of the DNA sequence. It is one of the simplest, most versatile, and precise methods of genetic manipulation. The rising prevalence of genetic disorders, along with the increasing demand for personalized medicine, is owing to the market growth. Additionally, significant investments in research and development by biotech and pharma sectors and governmental and regulatory support for gene editing applications play a vital role in fostering market development. However, off-target effects, ethical concerns surrounding human germline editing, and the potential for unintended consequences in the environment are significant issues limiting the market growth. Furthermore, the advancement of precision agriculture through crop design and the enhancement of cellular and genetic research methods create lucrative opportunities for market growth.

Regional Insights

In the Americas, particularly the United States and Canada, there is a significant emphasis on the advancement of CRISPR technology due to the high prevalence of genetic disorders and chronic diseases. Consumer needs are focused on personalized medicine and the potential of CRISPR to provide novel treatments. The United States is at the forefront in terms of CRISPR patents, with notable research being conducted by biotech giants and prestigious academic institutions. European Union (EU) countries have a robust regulatory framework guiding biotechnology applications that impact both consumer needs and purchasing behavior. The presence of stringent regulations, encouraging thorough, safe development on the one hand but potentially slowing innovation and adoption on the other. In the Middle East and Africa regions, CRISPR technology is still in the nascent stages of adoption. Due to varying levels of economic development and healthcare infrastructure, consumer needs and customer behavior differ significantly across these territories. The Asia Pacific region presents a diverse and rapidly evolving market for CRISPR gene editing. In China, CRISPR technology is receiving massive state and private investment, pushing forward substantial research and applications, especially in medicine and agriculture. Japan demonstrates a strong investment in the field, aligning its technological advancements with regulations sensitive to public concerns about genetic modification.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the CRISPR Gene Editing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Growing need for new vaccines and treatments for genetic diseases
• Increasing private and public investments in biotechnological and pharmaceutical sectors
• Adoption of CRISPR gene editing in space investigation

Market Restraints

• High cost of CRISPR therapies

Market Opportunities

• Advancements and improvements in CRISPR gene editing
• Potential use of CRISPR gene editing in the agriculture sector

Market Challenges

• Technical challenges and ethical concerns associated with CRISPR gene editing

Market Segmentation Analysis

• Technology: Increasing preference for CRISPR/Cas13 in application that involves the RNA manipulation
• End-use: Growing significance of CRISPR gene editing in pharmaceutical and biotechnology firms for therapeutic development and drug discovery

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CRISPR Gene Editing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CRISPR Gene Editing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers

Synthego and SeQure Dx formed a strategic alliance to advance the development of CRISPR therapeutics. This collaboration equips developers with an all-encompassing off-target editing analytic service, leveraging SeQure Dx's distinguished ONE-seq assay technology and Synthego's robust suite of synthetic guide RNAs. The seamless integration of these offerings promises to streamline the therapeutic development cycle, enhancing safety and efficiency while satisfying stringent regulatory standards.

CRISPR QC Raises USD 10 Million in Series A Financing Round

CRISPR QC, a startup based in San Diego, concluded a Series A funding round with a significant USD 10 million investment. Specializing in assessing CRISPR/Cas9 gene-editing endeavors, CRISPR QC is pioneering the field with its innovative platform that utilizes the CRISPR-Chip, a high-precision biosensor designed to evaluate CRISPR activity accurately. This funding triumph comes from a seed funding round that garnered USD 1.6 million, reflecting growing confidence and interest in CRISPR QC's potential to transform gene editing quality control.

Newcomer Tome Acquires Replace TX in USD 250 Million Gene Editing Deal

Tome Biosciences announced the acquisition of Replace Therapeutics in a strategic move, accelerating its footprint in the burgeoning gene editing sector. This acquisition underscores Tome's ambition to broaden its disease treatment portfolio and embodies the growing valuation of the gene editing market. Replace's contribution to Tome's suite with its ligase-mediated programmable genomic integration (L-PGI) complements Tome's existing large DNA edits, enhancing the company's capabilities in addressing various genetic conditions with high efficiency and specificity.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CRISPR Gene Editing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the CRISPR Gene Editing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Bio-Rad Laboratories, Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche AG, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Qiagen NV, Sherlock Biosciences, Inc., Thermo Fisher Scientific Inc., and ToolGen, Inc..

Market Segmentation & Coverage

This research report categorizes the CRISPR Gene Editing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Offering
• Reagents & Consumables
• Services
• Software & Systems
• Technology
• Anti-CRISPR Proteins
• CRISPR/Cas13
• CRISPR/Cas9
• CRISPR/Cpf1 (Cas12a)
• Application
• Diagnostics & Therapy Development
• Genetic Engineering
• Animal Genetic Engineering
• Cell Line Engineering
• Plant Genetic Engineering
• End-use
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year